MX2022013147A - Anticuerpos anti-interleucina 31 de acción prolongada para uso veterinario. - Google Patents

Anticuerpos anti-interleucina 31 de acción prolongada para uso veterinario.

Info

Publication number
MX2022013147A
MX2022013147A MX2022013147A MX2022013147A MX2022013147A MX 2022013147 A MX2022013147 A MX 2022013147A MX 2022013147 A MX2022013147 A MX 2022013147A MX 2022013147 A MX2022013147 A MX 2022013147A MX 2022013147 A MX2022013147 A MX 2022013147A
Authority
MX
Mexico
Prior art keywords
antibodies
long
acting anti
veterinary use
acting
Prior art date
Application number
MX2022013147A
Other languages
English (en)
Inventor
Shyr Jiann Li
Lam Nguyen
Hangjun Zhan
Richard Chin
Qingyi Chu
Original Assignee
Kindred Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindred Biosciences Inc filed Critical Kindred Biosciences Inc
Publication of MX2022013147A publication Critical patent/MX2022013147A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan varias modalidades relacionadas con anticuerpos anti-IL31 de acción prolongada que se unen a IL31 canina y/o IL31 felina; dichos anticuerpos pueden usarse en métodos para tratar afecciones inducidas por IL31 en animales de compañía, como caninos, felinos y equinos.
MX2022013147A 2020-04-22 2021-04-22 Anticuerpos anti-interleucina 31 de acción prolongada para uso veterinario. MX2022013147A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014033P 2020-04-22 2020-04-22
US202063014549P 2020-04-23 2020-04-23
PCT/US2021/028548 WO2021216810A1 (en) 2020-04-22 2021-04-22 Long-acting anti-il31 antibodies for veterinary use

Publications (1)

Publication Number Publication Date
MX2022013147A true MX2022013147A (es) 2023-02-09

Family

ID=78269992

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013147A MX2022013147A (es) 2020-04-22 2021-04-22 Anticuerpos anti-interleucina 31 de acción prolongada para uso veterinario.

Country Status (10)

Country Link
US (1) US20230312702A1 (es)
EP (1) EP4138914A4 (es)
JP (1) JP2023524643A (es)
KR (1) KR20230005875A (es)
CN (1) CN115666644A (es)
AU (1) AU2021258198A1 (es)
BR (1) BR112022021216A2 (es)
CA (1) CA3173864A1 (es)
MX (1) MX2022013147A (es)
WO (1) WO2021216810A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156180A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI564021B (zh) * 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
EP3526246A1 (en) * 2016-10-17 2019-08-21 Vetoquinol SA Modified antibody constant region
WO2018156180A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
WO2018156367A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
BR112020017703A2 (pt) * 2018-03-16 2021-03-09 Zoetis Services Llc Anticorpos monoclonais de interleucina-31 para uso veterinário
AU2019360271A1 (en) * 2018-10-18 2021-04-29 Elanco Us Inc. Fc variants with altered binding to neonatal Fc receptor (FcRn) for veterinary use
SG11202106478UA (en) * 2019-01-03 2021-07-29 Invetx Inc Compositions for increasing half-life of a therapeutic agent in canines and methods of use
CA3169301A1 (en) * 2020-03-18 2021-09-23 Shyr Jiann Li Anti-il4 receptor antibodies for veterinary use

Also Published As

Publication number Publication date
EP4138914A1 (en) 2023-03-01
CA3173864A1 (en) 2021-10-28
EP4138914A4 (en) 2024-05-22
KR20230005875A (ko) 2023-01-10
CN115666644A (zh) 2023-01-31
AU2021258198A1 (en) 2022-11-17
JP2023524643A (ja) 2023-06-13
WO2021216810A1 (en) 2021-10-28
BR112022021216A2 (pt) 2022-12-06
US20230312702A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
AU2018254542A1 (en) IL4/IL13 receptor molecule for veterinary use
MX2021004313A (es) Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
MX2015014739A (es) Alimento para animales que incluye aditivo de colesterol cationico.
ATE384433T1 (de) Kauspielzeug für tiere
AR096671A1 (es) Método para preparar una composición de aditivos para alimento para animales
MX2022002360A (es) Anticuerpos de anti-il31 para uso veterinario.
MX2021011335A (es) Antagonistas de ngf para uso medicinal.
MX362713B (es) Métodos y sistemas de alimentación para animales jóvenes del ganado usando compuestos sensitivos.
MX2022013147A (es) Anticuerpos anti-interleucina 31 de acción prolongada para uso veterinario.
MX336638B (es) Variantes sinteticas de fitasa.
MX2022013149A (es) Moléculas receptoras de interleucina 4/interleucina 13 para uso veterinario.
PH12014502423B1 (en) Treatment of poultry, pigs or fish for reducing the feed conversion ratio or increasing their bodyweight gain
MX2022011335A (es) Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
UA77302U (ru) Способ выращивания и кормления свиней в условиях малозатратной технологии
MX2021015590A (es) Metodos y composiciones con beneficios renales para felinos.
Henriksen et al. What is the best feeding strategy to adjust female minks’ body condition without compromising the welfare during the winter season?
Singh Studies on efficacy of area specific mineral mixture on general health, production and reproduction in dairy animals of central zone of Punjab
Seyoum et al. Prevalence of workrelated wound and associated risk factors in cart mules of adet town, north-western Ethiopia
Gebreyesus et al. Evaluation of growth trends in the short-eared Somali goat breed of eastern Ethiopia
TW200806191A (en) Feed additive
Campler The effect of housing on dairy cattle behavior during the transition period
Marshall et al. 104 Twelve-week provision of supplemental essential amino acids, fatty acids, and marine-based calcium does not impact horse hoof growth
Bae et al. Efficacy of enrofloxacin and silver sulfadiaznine topical otic suspension for the treatment of canine otitis externa
Wilkins African Queens
Fertner et al. Risk factors for antimicrobial use in Danish rosé veal calves. A register-based study